Literature DB >> 16135732

Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer.

D Moro-Sibilot1, A Aubert, S Diab, S Lantuejoul, P Fourneret, E Brambilla, C Brambilla, P Y Brichon.   

Abstract

Patients with nonsmall cell lung cancer (NSCLC) have been shown to have a higher prevalence of comorbidity associated with age and tobacco consumption. The objective of the present study was to determine the impact of comorbidity on survival after surgery of stage I NSCLC. In total, 588 consecutive patients operated on for a pathological stage I NSCLC between January 1, 1979 and December 31, 2003 were studied. Comorbidities were analysed individually. Overall comorbidity was assessed using the Charlson index of comorbidity (CCI). Survival data were collected for each patient from the date of operation, with a median duration of follow-up of 104 months. Survival analyses and Cox proportional hazards model analyses were used. The mean age of patients was 62.7 yrs, and 529 (89%) patients were male. The distribution of overall comorbidity severity was as follows. CCI grade 0: 47.1%; grade 1-2: 43.7%; grade 3-4: 8.3%; and grade > or =5: 0.8%. The 2, 3 and 5 yrs survival were 69, 62 and 50%, respectively. Multivariable analysis showed that T stage, age, a concomitant history of moderate-to-severe liver disease, a past history of cured cancer, cerebrovascular disease and CCI were independent predictors of survival (Hazard Ratio for CCI grade >2: 1.81; 95% confidence interval 1.25-2.63). In conclusion, comorbidity has a significant impact on survival after surgical resection of patients with stage I nonsmall cell lung cancer. The use of a validated index of comorbidity in prognostic analyses of resected nonsmall cell lung cancer is recommended.

Entities:  

Mesh:

Year:  2005        PMID: 16135732     DOI: 10.1183/09031936.05.00146004

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  28 in total

1.  Diabetes and the hospitalized patient : A cluster analytic framework for characterizing the role of sex, race and comorbidity from 2006 to 2011.

Authors:  Nisha Nataraj; Julie Simmons Ivy; Fay Cobb Payton; Joseph Norman
Journal:  Health Care Manag Sci       Date:  2017-07-22

2.  Regarding Ening et al. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification.

Authors:  Alba Fiorentino; Francesco Ricchetti; Rosario Mazzola; Sergio Fersino; Niccolò Giaj Levra; Filippo Alongi
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-25       Impact factor: 4.553

3.  Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer.

Authors:  Daniel H Ahn; Nishi Mehta; Jeffrey T Yorio; Yang Xie; Jingsheng Yan; David E Gerber
Journal:  Clin Lung Cancer       Date:  2013-07-22       Impact factor: 4.785

4.  Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC).

Authors:  Susana Cedrés; Isela Quispe; Pablo Martínez; Marina Longo; Eva Rodríguez; César Serrano; Eva Muñoz; Esther Pallisa; Enriqueta Felip
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

5.  Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies.

Authors:  Mario Balducci; Alba Fiorentino; Pasquale De Bonis; Silvia Chiesa; Stefania Manfrida; Giuseppe Roberto D'Agostino; Giovanna Mantini; Vincenzo Frascino; Gian Carlo Mattiucci; Berardino De Bari; Annunziato Mangiola; Francesco Miccichè; Maria Antonietta Gambacorta; Gabriella Colicchio; Alessio Giuseppe Morganti; Carmelo Anile; Vincenzo Valentini
Journal:  Med Oncol       Date:  2012-06-07       Impact factor: 3.064

6.  Risk factors for 30-day mortality after resection of lung cancer and prediction of their magnitude.

Authors:  Trond-Eirik Strand; Hans Rostad; Ronald A M Damhuis; Jarle Norstein
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

7.  Simplified comorbidity score for elderly patients undergoing thoracoscopic surgery for lung cancer.

Authors:  Tomohiro Haruki; Yohei Yurugi; Makoto Wakahara; Yuki Matsuoka; Ken Miwa; Kunio Araki; Yuji Taniguchi; Hiroshige Nakamura
Journal:  Surg Today       Date:  2016-10-03       Impact factor: 2.549

8.  The impact of cardiovascular comorbidities on the outcome of surgery for non-small-cell lung cancer.

Authors:  Tomoyoshi Takenaka; Masakazu Katsura; Yasunori Shikada; Syuichi Tsukamoto; Sadanori Takeo
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-12-05

9.  Cardiopulmonary co-morbidity: a critical negative prognostic predictor for pulmonary resection following preoperative chemotherapy and/or radiation therapy in lung cancer patients.

Authors:  Masayoshi Inoue; Meinoshin Okumura; Masato Minami; Hiroyuki Shiono; Noriyoshi Sawabata; Tomoki Utsumi; Yuko Ohno; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-08

10.  Effect of comorbidities on long-term outcomes after thoracoscopic surgery for stage I non-small cell lung cancer patients with chronic obstructive pulmonary disease.

Authors:  Takamasa Shibazaki; Makoto Odaka; Yuki Noda; You Tsukamoto; Shohei Mori; Hisatoshi Asano; Makoto Yamashita; Toshiaki Morikawa
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.